Lv4
696 积分 2023-12-25 加入
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
8小时前
待确认
Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial
12天前
已完结
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial
1个月前
已完结
Treatment Interruptions and Non-Adherence with Imatinib and Associated Healthcare Costs
1个月前
已完结
Comprehensive geriatric assessment in newly diagnosed older myeloma patients: a multicentre, prospective, non-interventional study
1个月前
已完结
Multicenter Randomized Double-Blind Phase III Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer
1个月前
已完结
Thyroid Cancer
1个月前
已完结
Multicenter Randomized Double-Blind Phase III Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer
1个月前
已完结
Radioiodine therapy in advanced differentiated thyroid cancer: Resistance and overcoming strategy
1个月前
已完结
Patient-Reported Outcomes and Mortality in Cutaneous Chronic Graft-vs-Host Disease
1个月前
已完结
皖公网安备34019202002308
